At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.

News of the cancellation came as Moderna revealed positive interim data from a phase 1/2 trial of its pandemic influenza vaccine, mRNA-1018, which targets the H5N8 bird flu subtype as well as ...

The study in healthy adults 18 years of age and older is split into two stages, with part A evaluating four vaccine candidates against H5N8, H7N9, H5 only, and H7 only, and part B zeroing in on a ...